

**Complete if Known**

(Use as many sheets as necessary)

Sheet 1

of	3
----	---

Attorney Docket Number	639-C-PCT-US
------------------------	--------------

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
/ESO/	6	WO 2006/007372	01-19-2006	Gary R. OSTROFF		
/ESO/	7	EP 0 759 089 B1	04-18-1995	Biotec Pharmacon ASA		

12/28/2009

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (02-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	10/565,484		
		Filing Date	January 17, 2006		
		First Named Inventor	CHEUNG, Nai-Kong V.		
		Art Unit	1623		
		Examiner Name	Eric Olson		
Sheet	2	of	3	Attorney Docket Number	639-C-PCT-US

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/ESO/	8	Australian Office Action, June 12, 2009, for SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, Australian Application No. 2008207369, Filed August 18, 2008, continuation-in-part of PCT/US07/01427	
/ESO/	9	Canadian Office Action, March 26, 2009, for SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, Canadian Application No. 2,434,938, Filed July 15, 2003, National Stage of PCT/US02/01276	
/ESO/	10	Chinese Office Action, July 24, 2009, for SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, Chinese Application No. 200480020356.6 (Atty. Dkt. #639-C-PCT-CN), Filed January 16, 2006, National Stage of PCT/US04/23099	
/ESO/	11	Chinese Office Action, February 27, 2009, for SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, Chinese Application No. 200480020356.6, Filed January 16, 2006, National Stage of PCT/US04/23099	
/ESO/	12	European Office Action, March 30, 2009, for SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, European Application No. 02 707 502.7, Filed August 4, 2003, National Stage of PCT/US02/01276	
/ESO/	13	Mexican Office Action, May 29, 2009, for SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, Mexican Application No. PA/a/2006/000615 (Atty. Dkt. #639-C-PCT-MX), Filed July 16, 2004, National Stage of PCT/US04/23099	
/ESO/	14	U.S. Advisory Action, August 6, 2009, for Nai-Kong V. CHEUNG, U.S. Serial No. 12/036,462, Filed February 25, 2008	
/ESO/	15	U.S. Advisory Action, July 10, 2009, for Nai-Kong V. CHEUNG, U.S. Serial No. 12/036,462, Filed February 25, 2008	
/ESO/	16	U.S. Office Action, June 2, 2009, for Nai-Kong V. CHEUNG, U.S. Serial No. 11/334,763, Filed January 17, 2006	
/ESO/	17	U.S. Office Action, April 17, 2009, for Nai-Kong V. CHEUNG, U.S. Serial No. 12/036,462, Filed February 25, 2008	

Examiner Signature	/Eric Olson/	Date Considered	12/28/2009
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (02-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/565,484		
		Filing Date	January 17, 2006		
		First Named Inventor	CHEUNG, Nai-Kong V.		
		Art Unit	1623		
		Examiner Name	Eric Olson		
Sheet	3	of	3	Attorney Docket Number	639-C-PCT-US

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/ESO/	18	ENGSTAD et al., 2002, "The effect of soluble beta-1,3-glucan and lipopolysaccharide on cytokine production and coagulation activation in whole blood", International Immunopharmacology, 2(11):1585-1597 (abstract only)	
/ESO/	19	DILLER et al., 1963, "The effect of Yeast Polysaccharides on Mouse Tumors", Cancer Research, 23:201-211	

Examiner Signature	/Eric Olson/	Date Considered	12/28/2009
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.